



10/22/08

JFW

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as Express Mail EM 155789170 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313, on the date shown below.

October 21, 2008
Signature: 
(Natalia Platonova)

Docket No.: HealOr-202-US
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Tamar TENNENBAUM, et al.

Application No.: 10/644,775

Filed: August 21, 2003

For: **METHODS AND PHARMACEUTICAL
COMPOSITIONS FOR HEALING WOUNDS**

Confirmation Number: 6931
Group Art Unit: 1647

Examiner: Marianne P. Allen

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference indicated on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

A copy of the reference indicated on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is

in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0624, under Order No. HealOr-202-US. A duplicate copy of this paper is enclosed.

Dated: October 21, 2008

Respectfully submitted,

By 
James R. Crawford

Registration No.: 39,155
FULBRIGHT & JAWORSKI L.L.P.
666 Fifth Avenue
New York, New York 10103
(212) 318-3000
(212) 318-3400 (Fax)
Attorneys for Applicant

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as Express Mail EM 155789170 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313, on the date shown below.


Dated:

October 21, 2008

Signature:

N. Platonova
(Natalia Platonova)

Docket No.: HealOr-202-US
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of:
Tamar TENNENBAUM, et al.

Application No.: 10/644,775

Confirmation Number: 6931
Group Art Unit: 1647

Filed: August 21, 2003

Examiner: Marianne P. Allen

For: METHODS AND PHARMACEUTICAL
COMPOSITIONS FOR HEALING WOUNDS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference indicated on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

A copy of the reference indicated on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is

in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0624, under Order No. HealOr-202-US. A duplicate copy of this paper is enclosed.

Dated: October 21, 2008

Respectfully submitted,

By 
James R. Crawford
Registration No.: 39,155
FULBRIGHT & JAWORSKI L.L.P.
666 Fifth Avenue
New York, New York 10103
(212) 318-3000
(212) 318-3400 (Fax)
Attorneys for Applicant